Free Trial
NYSEMKT:IBIO

iBio (IBIO) Stock Price, News & Analysis

iBio logo
$0.77 -0.01 (-1.48%)
As of 05/30/2025

About iBio Stock (NYSEMKT:IBIO)

Key Stats

Today's Range
$0.75
$0.79
50-Day Range
$0.70
$4.63
52-Week Range
N/A
Volume
177,037 shs
Average Volume
113,212 shs
Market Capitalization
$12.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Stock News Headlines

iBio (NYSEMKT:IBIO) Trading 3.2% Higher - Should You Buy?
Big Oil’s big pivot
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
Pharos iBio Co. Ltd.
iBio files to sell 246K shares of common stock for holders
iBio Announces New Investments from Board Members and Officers
See More Headlines

IBIO Stock Analysis - Frequently Asked Questions

iBio's stock was trading at $2.45 at the beginning of the year. Since then, IBIO shares have decreased by 68.6% and is now trading at $0.77.
View the best growth stocks for 2025 here
.

iBio, Inc. (NYSEMKT:IBIO) released its earnings results on Monday, November, 15th. The company reported ($20.00) earnings per share for the quarter, beating analysts' consensus estimates of ($25.00) by $5.00. The company had revenue of $0.21 million for the quarter.

iBio shares reverse split on the morning of Wednesday, November 29th 2023. The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Inovio Pharmaceuticals (INO), NIO (NIO), Vaxart (VXRT), Plug Power (PLUG), Tesla (TSLA), Advanced Micro Devices (AMD) and Ford Motor (F).

Company Calendar

Last Earnings
11/15/2021
Today
5/31/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSEMKT
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEMKT:IBIO
Employees
100
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$65.01 million
Pretax Margin
-41,546.00%

Debt

Sales & Book Value

Annual Sales
$375,000.00
Price / Cash Flow
N/A
Book Value
$2.64 per share
Price / Book
0.29

Miscellaneous

Free Float
3,445,000
Market Cap
$12.72 million
Optionable
N/A
Beta
1.19
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSEMKT:IBIO) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners